Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
|
|
Windhover and IN3 Webinars, divisions of Elsevier Business Intelligence, have served more than 3,000 participants with insightful, thought-provoking and action-oriented discussions of out industry -- straight from the minds of those in the know. And more than 300 of our insightful webinars are available for purchase or complimentary download.
| Upcoming Webinars |
New Windhover Webinars to be announced shortly.
Please check back later. |
Information & registration |
|
|
New IN3 Webinars to be announced shortly.
Please check back later. |
Information & registration |
|
|
Webinar Cancellation Policy:
No refunds or credits will be given one week prior to the scheduled
webinar, or after the webinar presentation materials
and access instructions have been sent to participants. In lieu
of cancellation, you may substitute another delegate from your
company as a replacement.
|
| Archived Webinars |
Previous webinars are available for purchase
via digital download and contain the original audio in Windows Media®
format with accompanying presentation slides (when applicable) in Adobe®
PDF format.
|
|
February 11,
2010 -
Capitalizing on New FDA Guidance: The Promise and Perils of Disseminating Scientific Literature About Off-Label Use of Medical Devices |
|
|
January 21,
2010 -
FDA's Enforcement Initiative: What should you do differently? |
|
|
January 20,
2010 -
The Road to FDA Approval: Advisory Committee Survival Strategies |
|
|
|
December 15,
2009 -
Public Interest/Private Sector: Collaboration and Conflict in Drug Development |
|
|
December 11,
2009 -
Avoiding the 14 Biggest Mistakes Made by Emerging Life Science Companies in Reimbursement, Valuation, Investor Presentations and Regulatory Strategy |
|
|
December 9,
2009 -
Patient Registries: Integrating New Requirements and Evolving Best Practices |
|
|
November 24,
2009 -
Dealing with Payors: Creative Strategies to Optimize your Drug's Positioning & Reimbursement |
|
|
October 21,
2009 -
Pfiguring Out The Pfizer Settlements |
|
|
October 14,
2009 -
Biotech and Pharma Dealmaking in the Era of Uncertainty |
|
|
October 1,
2009 -
FDA Requirements for Training at Device Facilities: Are you in compliance? |
|
|
September 30,
2009 -
Product Liability: Strategies for Success when Medical Technology and Life Sciences Companies Come Under Attack |
|
|
July 22,
2009 -
FDA Requirements for Device Software: Are You in Compliance? |
|
|
June 4,
2009 -
How to Transform Your Commercial Strategies for Success in the 21st Century |
|
|
May 20,
2009 -
How to Navigate Changing Trends in DTC Advertising |
|
|
|
August 27, 2008
- Webinar: Anti-Bribery Compliance in China – Avoiding
the Pitfalls |
|
| July 17, 2008 -
Webinar: Reviving the Primary Care Market: Strategic Considerations and New Growth Alternatives |
|
| July 10, 2008 -
Webinar: The Road to FDA Approval: Advisory Committee Survival Strategies |
|
| June
26, 2008 -
Webinar: How To Maximize Your Reimbursement Value Through
Pharmacoeconomic and Outcomes Research: Adapting to the Changing
Dossier Environment |
|
| June
12, 2008 - Webinar:
Managing Current Challenges to Ensure Future Growth |
|
| May
22, 2008 - Webinar
- "The Secrets to Creating an Effective VC/Investor Presentation:
What Every Investor Wants to Hear from You!" |
|
| March
12, 2008 - Webinar
- "Medical
Devices: Surviving the New World of Government Investigation,
Enforcement and Settlements" |
|
| January
31, 2008 - Webinar
- "4th
Annual Overheard at JP Morgan/H&Q: Key, Unbiased Take-Aways
for Your Whole Team " |
|
|
|
For more information or to register for these insightful
and interactive webinars, please contact:
Alexandria Riley
Conference Coordinator
Email: a.riley@elsevier.com
Phone: (203) 838-4401 x113
or register online via the links above.
|
|
 |
|
 |
|
|
| |
 |
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications. . . [MORE] (IN VIVO)
Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. . . [MORE] (Start-Up)
The Future of Drug-Eluting Stents Part II: Biodegradable Platforms
The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. . . [MORE] (Medtech Insight)
Health Reform in the Balance: What It Means for Biopharma
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|
